ArticleClinical kidney journal2022
Stopping versus continuing renin-angiotensin-system inhibitors after acute kidney injury and adverse clinical outcomes: an observational study from routine care data.
Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis.BMC infectious diseases · 2023Pooled it
- Impact of renin-angiotensin system inhibitors discontinuation in advanced chronic kidney disease: a target trial emulation.Clinical kidney journal · 2026Article
- Post-nephrectomy outcomes in COVID-19 and non-COVID-19 Patients using ACEi, ARB and SGLT2i: a N3C database study.International urology and nephrology · 2026Article
- Renin-angiotensin system inhibitors (RASi) are not nephrotoxic - they protect the kidneys and the heart.Clinical medicine (London, England) · 2026Review
- Top ten tips to manage patients after acute kidney injury.Clinical kidney journal · 2026Review
- Optimizing Proteinuria Evaluation and Management after Acute Kidney Injury: Insights from the Chronic Renal Insufficiency Cohort Study.Kidney360 · 2026Article
- Implementing the Acute Kidney Injury in Care Transitions (ACT) Program: Results From a Mixed Methods Feasibility Study.Kidney medicine · 2026Article
- A Multipronged Intervention to Improve Outpatient Care Following Hospitalization With Acute Kidney Injury: An Implementation Study Protocol.Canadian journal of kidney health and disease · 2026Article
- Prevention and Management of Perioperative Acute Kidney Injury: A Narrative Review.Diseases (Basel, Switzerland) · 2025Review
- The 'nephrotoxins' were stopped: what is in a name and its impact on kidney and cardiac health?Internal medicine journal · 2025Review
- Acute Kidney Injury in Care Transitions (ACT): A Randomized Controlled Feasibility Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025Article
- Impact of Different Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blocker Resumption Timing on Post Acute Kidney Injury Outcomes.Kidney international reports · 2024Article
- Drug stewardship in chronic kidney disease to achieve effective and safe medication use.Nature reviews. Nephrology · 2024Review
- Blood Pressure, Readmission, and Mortality Among Patients Hospitalized With Acute Kidney Injury.JAMA network open · 2024Article
- Pharmacological strategies to manage hyperkalaemia: out with the old, in with the new? Not so fast….Clinical kidney journal · 2023Article
- Stopping kidney protection in the elderly following acute kidney injury: think mortality.Clinical kidney journal · 2022Article
- Collaborative Management of Hyperkalemia in Patients with Complex Heart Failure.Case reports in nephrology and dialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The risk-benefit ratio of continuing with renin-angiotensin system inhibitors (RASi) after an episode of acute kidney injury (AKI) is unclear. While stopping RASi may prevent recurrent AKI or hyperkalaemia, it may deprive patients of the cardiovascular benefits of using RASi. Methods: We analysed outcomes of long-term RASi users experiencing AKI (stage 2 or 3, or clinically coded) during hospitalization in Stockholm and Sweden during 2007-18. We compared stopping RASi within 3 months after discharge with continuing RASi. The primary study outcome was the composite of all-cause mortality, myocardial infarction (MI) and stroke. Recurrent AKI was our secondary outcome and we considered hyperkalaemia as a positive control outcome. Propensity score overlap weighted Cox models were used to estimate hazard ratios (HRs), balancing 75 confounders. Weighted absolute risk differences (ARDs) were also determined. Results: We included 10 165 individuals, of whom 4429 stopped and 5736 continued RASi, with a median follow-up of 2.3 years. The median age was 78 years; 45% were women and median kidney function before the index episode of AKI was 55 mL/min/1.73 m Discussion: Stopping RASi use among survivors of moderate-to-severe AKI was associated with a similar risk of recurrent AKI, but higher risk of the composite of death, MI and stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.